In the intricate search for cancer cures, the most promising targets are often the smallest: short protein fragments, or peptides, presented on the surface of cells. These fragments are flags waved by the immune system, signaling whether a cell is healthy or diseased. For developers of T-cell therapies and cancer vaccines, accurately identifying which of these flags are unique to tumors,and safe to target,is a monumental, data-starved challenge. Alithea Bio, a German biotech founded in 2019, is betting its future on building the map.
The company's core asset is a growing proprietary database of HLA-presented peptides, compiled from thousands of patient samples. The goal is to give pharmaceutical researchers a clearer, more quantitative picture of the immune landscape in both health and disease, moving beyond theoretical predictions to observed biology. This data-centric approach forms the foundation of its two main software tools: HLA-Compass for peptide characterization and NeoZOOM for predicting off-target toxicities [Alithea Bio website].
The immunopeptidomics wedge
Alithea's entry point is the complex, high-stakes field of target validation. When designing a therapy that instructs the immune system to attack cancer, a misstep can be catastrophic; targeting a peptide also found on healthy tissue can lead to severe, even fatal, side effects. The company's platform aims to de-risk this process by applying mass spectrometry and bioinformatics to directly measure and catalog the peptides cells present, rather than relying solely on algorithmic predictions.
Its reported database, drawn from an estimated 3,000 samples, covers 1.1 million ligands and their abundance across conditions [PMWC]. This empirical dataset is the differentiator. By quantifying what is actually presented on cells, Alithea provides a reality check for drug candidates, helping researchers prioritize neoantigens with high tumor specificity and low risk of collateral damage.
A team built for translation
The company's leadership reflects a blend of scientific depth and commercial focus, a necessary combination for translating academic research into industry tools. Chief Scientific Officer and co-founder Tim Fugmann brings direct technical expertise, with a background in applying HLA peptidomics technologies and an education from ETH Zürich [LinkedIn, Bruker webinar]. CEO Fanny Giannou, who holds a master's in international economics, oversees business strategy and external partnerships [Crunchbase, Startup Greece podcast].
The company has engaged with early-stage public funding and recognition programs, a common path for European deep-tech ventures. These include participation in the BadenCampus accelerator, the German ZIM grant program, and the Women TechEU award in 2024, which provided support to Giannou [LinkedIn]. While detailed funding rounds and valuations are not public, these non-dilutive grants suggest initial validation from public-sector bodies focused on science commercialization.
| Role | Name | Key Background |
|---|---|---|
| CEO & Co-Founder | Fanny Giannou | Master's in International Economics; Women TechEU awardee [Crunchbase, Startup Greece]. |
| Chief Scientific Officer & Co-Founder | Tim Fugmann | Experienced in HLA peptidomics applications; educated at ETH Zürich [LinkedIn, Bruker]. |
| Chief Financial Officer & Co-Founder | (Not named in public sources) | Appointed per company website [Alithea Bio]. |
Navigating an unproven commercial path
The ambition is clear, but the path to commercial scale in the pharmaceutical tools sector is long and capital-intensive. Alithea Bio's public track record is still forming. The company states it has completed its first commercial contracts, a critical early milestone, but has not named any pharmaceutical or biotech partners [Alithea Bio]. In a field where credibility is built on published case studies and named logos, this opacity is a hurdle. Furthermore, the core technology requires continuous investment to expand the peptide database and refine its AI models, a effort that will eventually demand significant venture capital beyond its initial grants.
The competitive landscape, while not naming direct rivals, is implicitly crowded. Large CROs offer mass spectrometry services, and several bioinformatics firms provide in silico prediction tools for antigen discovery. Alithea's bet is that integrating wet-lab data generation with specialized software creates a defensible niche. Its success will hinge on convincing drug developers that its integrated platform offers uniquely reliable data, justifying its use over assembling services from multiple providers.
- The data moat. The value of the 1.1 million-peptide database compounds with each new sample, creating a barrier to entry for new players [PMWC].
- The regulatory tailwind. Increased FDA scrutiny of immunotherapy safety profiles creates a market for tools that rigorously quantify off-target risk [Pulse Raman analysis].
- The adoption challenge. As a new entrant, Alithea must displace incumbent workflows and prove its platform meaningfully accelerates or de-risks the R&D timeline for time-pressed pharma teams.
For patients with advanced solid tumors, the current standard of care often involves a sequential march through chemotherapy, radiation, and, if they are eligible and a target is found, a targeted therapy or immunotherapy. The process of discovering a truly tumor-specific antigen remains slow and prone to failure, leaving many without a viable therapeutic option. Alithea Bio's long-term vision is to compress that discovery timeline and improve its success rate, providing developers with the tools to design therapies that are both potent and precise. The company's next twelve months will likely be defined by its ability to convert its first contracts into published validation studies and to secure the growth capital needed to scale its data-generation engine. In the meticulous world of immuno-oncology, building a better map is not an academic exercise; it's a prerequisite for building better cures.
Sources
- [Alithea Bio, Unknown] Company homepage and product descriptions | https://alithea-bio.com/
- [PMWC, Unknown] Tim Fugmann speaker biography referencing HLA peptide database | https://www.pmwcintl.com/speaker/tim-fugmann-478_alithea-bio-ug_2023sv
- [Crunchbase, Unknown] Fanny Giannou profile | https://www.crunchbase.com/person/fanny-giannou
- [LinkedIn, Unknown] Tim Fugmann professional profile | https://www.linkedin.com/in/tim-fugmann-a1639914/
- [Bruker, Unknown] Webinar featuring Tim Fugmann of Alithea Bio | https://www.bruker.com/en/news-and-events/webinars/2024/unlocking-the-full-potential-of-immunopeptidomics-with-the-timstof-ultra.html
- [Startup Greece, Unknown] Podcast episode with Fanny Giannou | https://startup-greece.org/podcasts/podcasts-immunotherapy-alithea-bio/
- [Alithea Bio, Unknown] About Us page referencing first commercial contracts | https://alithea-bio.com/about-us/